1Ruhinstein E, Kollef MH, Nathwani D. Pneumonia caused by methiciUin-resistartt Staphylococcus aureus. Clin Infect Dis,2008, 46 Suppl 5 : S378-S385.
2Sakoulas G, Moellering RC Jr. Increasing antibiotic resistanee among methicillin-resistant Staphylococcus aureas strains. Clin Infect Dis,2008,46 Suppl 5 :S360-S367.
3Wunderink RG, Rello J, Cammarata SK, et al. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-risistant Staphylococcus aureus nosocomial pneumonia. Chest ,2003,124 : 1789-1797.
4Centers for Disease Control and Prevention ( CDC ). Staphylococcus aureus resistant to vancomycin United States, 2002 [J]. MMWR Morb Mortal Wkly Rep, 2002, 51 (26) :565.
5Vanhoof R, Nyssen HJ, Van Bossuyt E,et al. Aminoglycoside resistance in Gram-negative blood isolates from various hospitals in Belgium and the Grand Duchy of Luxembourg. Aminoglycoside Resistance Study Group [ J ] . J Antimicrob Chemother, 1999,44 (4) : 483.
6Bell J, Tumidge J. SENTRY Antimicrobial Surveillance Program Asia-Pacific region and South Africa [J]. Commun Dis Intell,2003,27 (Suppl) : S61.
7El Mouedden M, Laurent G, Mingeot-Leclercq MP, et al. Apoptosis in renal proximal tubules of rats treated with low doses of aminoglycosides [ J] . Antimicrob Agents Chemother, 2000,44(3) :665.
8ougier F, Claude D, Maurin M, et al. Aminoglycoside nephrotoxicity: modeling, simulation, and control [ J ]. Antimicrob Agents Chemother, 2003 ;47(3) : 1 010.
9Craig WA. Post-antibiotic effects in experimental infection models: relationship to in-vitro phenomena and to treatment of infections in man [J]. J Antimicrob Chemother, 1993, 31 (Suppl D) : 149.
10Tod M, Padoin C, Petitjean O. Clinical pharmacokinetics and pharmacodynamics of isepamicin [ J ]. Clin Pharmacokinet, 2000,38(3) :205.
